Epigenetic regulation of Keap1-Nrf2 signaling

被引:210
作者
Guo, Yue [1 ]
Yu, Siwang [2 ,3 ]
Zhang, Chengyue [1 ]
Kong, Ah-Ng Tony [1 ]
机构
[1] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA
[2] State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
[3] Peking Univ, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
基金
中国国家自然科学基金;
关键词
Nrf2; Keap1; Epigenetic; DNA methylation; Histone modification; MicroRNAs;
D O I
10.1016/j.freeradbiomed.2015.06.013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
The kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid 2-related factor 2 (Nrf2) signaling axis serves as a "master regulator" in response to oxidative/electrophilic stresses and chemical insults through the coordinated induction of a wide array of cytoprotective genes. Therefore, activation of Nrf2 is considered to be an important approach for preventing chronic diseases triggered by stresses and toxins, including cancer. Despite extensive studies suggested that the Keap1-Nrf2 signaling pathway is subject to multiple layers of regulation at the transcriptional, translational, and post-translational levels, the potential epigenetic regulation of Nrf2 and Keapl has begun to be recognized only in recent years. Epigenetic modifications, heritable alterations in gene expression that occur without changes in the primary DNA sequence, have been reported to be profoundly involved in oxidative stress responses. In this review, we discuss the latest findings regarding the epigenetic regulation of Keapl-Nrf2 signaling by DNA methylation, histone modification, and microRNAs. The crosstalk among these epigenetic modifications in the regulation of Keapl-Nrf2 signaling pathways is also discussed. Studies of the epigenetic modification of Nrf2 and Keapl have not only enhanced our understanding of this complex cellular defense system but have also provided potential new therapeutic targets for the prevention of certain diseases.
引用
收藏
页码:337 / 349
页数:13
相关论文
共 124 条
[1]
Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., Yamamoto M., Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain, Genes Dev, 13, pp. 76-86, (1999)
[2]
Wakabayashi N., Slocum S.L., Skoko J.J., Shin S., Kensler T.W., When Nrf2 talks, who's listening?, Antioxidants & Redox Signaling, 13, pp. 1649-1663, (2010)
[3]
Jeong W.S., Jun M., Kong A.N., Nrf2: A potential molecular target for cancer chemoprevention by natural compounds, Antioxidants & Redox Signaling, 8, pp. 99-106, (2006)
[4]
Hayes J.D., McMahon M., Nrf2 and Keap1 mutations: Permanent activation of an adaptive response in cancer, Trends in Biochemical Sciences, 34, pp. 176-188, (2009)
[5]
Sporn M.B., Liby K.T., Nrf2 and cancer: The good, the bad and the importance of context, Nature Reviews. Cancer, 12, pp. 564-571, (2012)
[6]
Wang X.J., Sun Z., Villeneuve N.F., Zhang S., Zhao F., Li Y., Chen W., Yi X., Zheng W., Wondrak G.T., Wong P.K., Zhang D.D., Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2, Carcinogenesis, 29, pp. 1235-1243, (2008)
[7]
Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O., Herman J.G., Baylin S.B., Sidransky D., Gabrielson E., Brock M.V., Biswal S., Dysfunctional Keap1-Nrf2 interaction in non-small-cell lung cancer, PLoS Medicine, 3, (2006)
[8]
Solis L.M., Behrens C., Dong W., Suraokar M., Ozburn N.C., Moran C.A., Corvalan A.H., Biswal S., Swisher S.G., Bekele B.N., Minna J.D., Stewart D.J., Wistuba, II. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 16, pp. 3743-3753, (2010)
[9]
Wolffe A.P., Matzke M.A., Epigenetics: Regulation through repression, Science, 286, pp. 481-486, (1999)
[10]
Mattick J.S., Makunin I.V., Non-coding RNA, Human Molecular Genetics, 15, (2006)